Squarepoint
KYTX icon

Squarepoint’s Kyverna Therapeutics KYTX Stock Holding History

Squarepoint’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$738K Sell
82,867
-64,111
-44% -$569K ﹤0.01% 3136
2026
Q1 		$1.27M Buy
146,978
+8,110
+6% +$67.6K ﹤0.01% 2570
2025
Q4 		$1.31M Buy
+138,868
New +$1.03M ﹤0.01% 2391
2025
Q3 		– Sell
-29,730
Closed -$91.3K – 5109
2025
Q2 		$91.3K Buy
+29,730
New +$73.5K ﹤0.01% 4191
2025
Q1 		– Sell
-11,488
Closed -$43K – 5562
2024
Q4 		$43K Buy
+11,488
New +$55K ﹤0.01% 4868
2024
Q2 		– Sell
-88,423
Closed -$2.2M – 4747
2024
Q1 		$2.2M Buy
+88,423
New +$2.47M ﹤0.01% 2026

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Squarepoint's KYTX Position: Q2 2026 in Review

Squarepoint reduced its Kyverna Therapeutics (KYTX) stake by 44% in Q2 2026, selling an estimated $569K and leaving 82,867 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #3136.

Squarepoint first reported a position in KYTX in Q1 2024 and has held it in 6 quarters since. The position peaked at $2.2M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Squarepoint held 82,867 shares of Kyverna Therapeutics worth $738K as of Q2 2026.
  • Squarepoint sold 64,111 Kyverna Therapeutics shares in Q2 2026, an estimated $569K.
  • Kyverna Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3136 holding.
  • Squarepoint first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Squarepoint's Kyverna Therapeutics position peaked at $2.2M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.